-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

670 MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or “Add-on” to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis

Program: Oral and Poster Abstracts
Type: Oral
Session: 634. Myeloproliferative Syndromes: Clinical: JAK Inhibitors and Combination Therapies
Hematology Disease Topics & Pathways:
Diseases, Non-Biological, Therapies, MPN, Clinically relevant, Myeloid Malignancies
Monday, December 9, 2019: 11:15 AM
W311EFGH, Level 3 (Orange County Convention Center)

John Mascarenhas, MD1, Marina Kremyanskaya2*, Ronald Hoffman, MD3, Prithviraj Bose, MD4, Moshe Talpaz, MD 5, Claire N Harrison, Professor6, Vikas Gupta, MD, FRCP, FRCPath7, Brian Leber, MD8, Shireen Sirhan, MD9, Sujan Kabir, MD10*, Adrian Senderowicz, MD10*, James Shao, MS10*, Jennifer Mertz, PhD10*, Patrick Trojer, PhD10* and Srdan Verstovsek, MD, PhD11

1Tisch Cancer Institute, Division of Hematology/Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
2Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Hospital, New York, NY
3Division of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
4MD Anderson Cancer Center, Houston, TX
5Rogel Cancer Center, The University of Michigan, Ann Arbor, MI
6Guy's and St Thomas' Hospital, London, United Kingdom
7Leukemia Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
8Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, ON, Canada
9Division of Hematology, Jewish General Hospital, Montreal, QC, Canada
10Constellation Pharmaceuticals, Cambridge, MA
11University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX

Background: CPI-0610, a selective and potent small molecule BETi, has shown clinical activity and a wide therapeutic window in a Phase 1 lymphoma study (Blum KA, 2018). BET proteins regulate key oncogenic pathways, including NFκB and TGFβ signaling which are important drivers of pro-inflammatory cytokine (Ck) expression and bone marrow fibrosis, respectively, and are implicated in myelofibrosis (MF) pathogenesis. Ruxolitinib (rux), a Janus kinase 1/2 inhibitor (JAKi), is the only approved therapy for MF, and primarily reduces spleen volume and provides symptomatic relief. Patients (pts) receiving rux may achieve suboptimal responses or can develop treatment-emergent anemia and worsening transfusion dependence. There is no approved treatment for pts who are refractory/intolerant to rux. Preclinical studies suggest that a combination of BETi and JAKi can result in synergistic reduction of splenomegaly, bone marrow (BM) fibrosis and mutant cell burden (Kleppe, 2018). Our objective is to evaluate CPI-0610 alone or “add-on” to rux (CPI-0610 + rux) in MF pts who are refractory/intolerant or have inadequate response to rux.

Method: This is a global, multicenter, open label Phase 2 study (MANIFEST) of CPI-0610 monotherapy in MF pts who are refractory/intolerant to rux (Arm 1) or CPI-0610 + rux in MF pts who have suboptimal response to rux (Arm 2). Pts are further stratified based on transfusion dependence status [transfusion dependent (TD), defined as an average of ≥2 units per month over 12 wks, or non-TD cohorts]. The starting dose of CPI-0610 is 125 mg daily on days 1-14 of a 21-day cycle in both arms. Primary endpoint: spleen volume response (SVR) for non-TD cohorts or TD to transfusion independence (TI, no transfusion for consecutive 12 wks) conversion for TD cohorts; secondary endpoints: change in total symptom score (TSS) per MFSAF v4.0, patient global impression of change (PGIC), safety and PK; additional endpoints: changes in proinflammatory Ck levels, BM morphology and mutant allele burden.

Results: As of 27 June 2019, 48 pts enrolled- 12 treated with CPI-0610 monotherapy (Arm 1) and 36 with CPI-0610 + rux (Arm 2). At baseline, median age: 69 years (41-88), gender: 28 (58%) male, ECOG ≤1: 45 (94%) pts, primary MF: 33 (69%) pts, DIPSS score high: 10 (21%) pts, median platelet: 199 x 109/L (77-895), 34 (71%) pts with Hgb <10 g/dL, median spleen volume: 2183 cc (123-3909), median TSS: 17.6 (1.4-56), 46 (96%) pts had ≥1 JAK2/MPL/CALR mutations, and 34 (71%) pts had HMR (high molecular risk) mutations. 33 (69%) pts on treatment for ≥ 12 wks, 4 on treatment for > 18 months. Spleen volume reduction observed in 29 of 31 (94%) pts (median best change: -17% [range: -50.7, 10.2]) (Fig. 1A). TSS improvement reported in 26 of 28 (93%) pts (median best change: -46.4% [range: -95.3%, 27%]), 11 (39%) pts with ≥50% TSS improvement (Fig. 1B). PGIC improvement score in 28 of 33 (85%) pts; 21 (64%) reported much or very much improved scores. Increase in hemoglobin by 1.5 mg/dL post-baseline observed with both CPI-0610 monotherapy (4 of 8, 50%) and CPI-0610 + rux (4 of 25, 16%)). Improvement in BM fibrosis and/or reticulin by ≥1 Gr reported in 7 of 12 (58%) evaluable pts with baseline and 1 post-baseline biopsy and as early as 6-months of CPI-0610 treatment. 4 TD pts in Arm 2 treated with CPI-0610 + rux converted to TI- 2 of whom are TI for >36 wks, no longer anemic, and showed spleen volume reduction, improvement in symptom and BM fibrosis; 12 additional pts are being monitored for potential TI conversion. 41 pts remain active on treatment and 7 pts discontinued, including 1 pt, initially transplant ineligible, underwent stem cell transplantation after 6 cycles of CPI-0610 + rux treatment. Most common (≥20%) treatment-emergent adverse events (TEAE) of any Gr include diarrhea, nausea, cough and upper respiratory tract infection. Most common (≥5%) ≥3 Gr TEAE include anemia (8.3%) and thrombocytopenia (8.3%, asymptomatic, non-cumulative and generally reversible).

Conclusions: Preliminary data indicate that CPI-0610 alone or “add-on” to rux is generally well-tolerated and provides clinical benefits in MF pts with inadequate responses or who are refractory to rux. Improvement in BM fibrosis and anemia responses indicate the potential for meaningful disease modification. Based on the available data, Arm 2 TD cohort has achieved proof-of-concept for TI. Further expansion of the MANIFEST study is ongoing. Updated data will be presented.

Disclosures: Mascarenhas: Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Research Funding; Roche: Consultancy, Research Funding; Merck: Research Funding; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; CTI Biopharma: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Research Funding; Promedior: Research Funding; Merus: Research Funding; Pharmaessentia: Consultancy, Membership on an entity's Board of Directors or advisory committees. Kremyanskaya: La Jolla: Consultancy; Incyte, Celgene, Constellation, Protagonist.: Research Funding. Hoffman: Merus: Research Funding. Bose: Celgene Corporation: Consultancy, Research Funding; Incyte Corporation: Consultancy, Research Funding, Speakers Bureau; Blueprint Medicine Corporation: Consultancy, Research Funding; Kartos: Consultancy, Research Funding; Constellation: Research Funding; Pfizer: Research Funding; Astellas: Research Funding; NS Pharma: Research Funding; Promedior: Research Funding; CTI BioPharma: Research Funding. Talpaz: Imago BioSciences: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; CTI BioPharma: Research Funding; Constellation: Research Funding; Incyte: Research Funding; Novartis: Research Funding; Samus Therapeutics: Research Funding. Harrison: Sierra Oncology: Honoraria; Incyte: Speakers Bureau; AOP: Honoraria; Gilead: Speakers Bureau; Janssen: Speakers Bureau; Shire: Speakers Bureau; Promedior: Honoraria; Roche: Honoraria; Novartis: Honoraria, Research Funding, Speakers Bureau; Celgene: Honoraria, Speakers Bureau; CTI: Speakers Bureau. Gupta: Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sierra Oncology: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte: Honoraria, Research Funding. Leber: Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astellas: Honoraria, Membership on an entity's Board of Directors or advisory committees; Jazz: Honoraria, Membership on an entity's Board of Directors or advisory committees; Alexion: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Sirhan: Celgene: Consultancy; Novartis: Consultancy, Speakers Bureau. Kabir: Constellation Pharmaceuticals: Employment. Senderowicz: Constellation Pharmaceuticals: Employment; Puma Biotechnology: Membership on an entity's Board of Directors or advisory committees. Shao: Constellation Pharmaceuticals: Employment. Mertz: Constellation Pharmaceuticals: Employment, Equity Ownership. Trojer: Constellation Pharmaceuticals: Employment, Equity Ownership. Verstovsek: CTI BioPharma Corp: Research Funding; Genetech: Research Funding; Blueprint Medicines Corp: Research Funding; Novartis: Consultancy, Research Funding; Sierra Oncology: Research Funding; Pharma Essentia: Research Funding; Astrazeneca: Research Funding; Ital Pharma: Research Funding; Protaganist Therapeutics: Research Funding; Constellation: Consultancy; Pragmatist: Consultancy; Incyte: Research Funding; Roche: Research Funding; NS Pharma: Research Funding; Celgene: Consultancy, Research Funding; Gilead: Research Funding; Promedior: Research Funding.

*signifies non-member of ASH